Increasing public spending on healthcare in Central and Eastern Europe (CEE) could not only result in healthier populations, it could also improve the region’s economic prosperity.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh